Nearly 25% of all cancers have gene amplifications
More than 400,000 newly diagnosed cancers each year in the US alone harbor oncogene amplifications. Unfortunately, there are no effective treatment options for the vast majority of these patients, resulting in poor prognosis and survival.
While progress in treating cancers with gene mutations continues to advance, patients whose cancers harbor gene amplifications have been left behind.
The current generation of targeted therapies and immunotherapies fail to provide adequate solutions to patients with oncogene amplified tumors.
Why We’re HereecDNA drive oncogene amplifications
Extrachromosomal DNA (ecDNA), circular DNA structures located outside of chromosomes, were first discovered in the 1960s.
Today, we understand these pervasive circles play an aggressive and central role in tumor evolution. Encoding oncogenes, ecDNA enable cancer to rapidly evolve and evade therapeutic intervention.
Boundless Bio’s differentiated approach exploits the unique vulnerabilities of ecDNA in cancer cells.
Learn more about ecDNA:ecDNA are a therapeutically actionable vulnerability in cancer cells
ecDNA are rarely seen in healthy cells, but are found in nearly half of all solid tumor cancers. Boundless Bio’s comprehensive approach to understanding the utilization of ecDNA by cancer, allows us to identify and therapeutically exploit the unique vulnerabilities of ecDNA in cancer cells.
What We Do
Why Boundless Bio?
Boundless Bio is the only company dedicated to treating oncogene amplified cancers and is the leading precision oncology company in the burgeoning field of ecDNA.
With boundless innovation and boundless energy, our team of professional drug hunters is developing powerful new cancer medicines that eliminate cancer cells’ ability to employ ecDNA to survive.
Who We Are